Investors seeking to outperform the market often focus on hand-picking stocks. Selecting the right ones has proven to be a key factor in boosting wealth.
In the latest session, Cogent Biosciences Inc (NASDAQ: COGT) closed at $14.72 up 2.08% from its previous closing price of $14.42. In other words, the price has increased by $2.08 from its previous closing price. On the day, 1.72 million shares were traded. COGT stock price reached its highest trading level at $15.085 during the session, while it also had its lowest trading level at $14.21.
Ratios:
For a deeper understanding of Cogent Biosciences Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.19 and its Current Ratio is at 4.19. In the meantime, Its Debt-to-Equity ratio is 0.20 whereas as Long-Term Debt/Eq ratio is at 0.20.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of. The stock’s future direction. In the most recent recommendation for this company, Stifel on October 16, 2025, initiated with a Hold rating and assigned the stock a target price of $16.
On September 03, 2025, Raymond James started tracking the stock assigning a Strong Buy rating and target price of $30.
On March 07, 2025, Scotiabank started tracking the stock assigning a Sector Outperform rating and target price of $17.Scotiabank initiated its Sector Outperform rating on March 07, 2025, with a $17 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Jul 10 ’25 when Fairmount Funds Management LLC bought 2,777,777 shares for $9.00 per share. The transaction valued at 24,999,993 led to the insider holds 9,003,418 shares of the business.
Pinnow Cole bought 43,750 shares of COGT for $332,412 on Jan 14 ’25. The Chief Commercial Officer now owns 45,848 shares after completing the transaction at $7.60 per share.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, COGT now has a Market Capitalization of 2056395776 and an Enterprise Value of 1988214144.
Stock Price History:
The Beta on a monthly basis for COGT is 0.66, which has changed by 0.41234088 over the last 52 weeks, in comparison to a change of 0.13355756 over the same period for the S&P500. Over the past 52 weeks, COGT has reached a high of $17.15, while it has fallen to a 52-week low of $3.72. The 50-Day Moving Average of the stock is 2.65%, while the 200-Day Moving Average is calculated to be 55.75%.
Shares Statistics:
For the past three months, COGT has traded an average of 1.96M shares per day and 2840900 over the past ten days. A total of 139.70M shares are outstanding, with a floating share count of 112.56M. Insiders hold about 19.43% of the company’s shares, while institutions hold 88.14% stake in the company. Shares short for COGT as of 1760486400 were 16276722 with a Short Ratio of 8.32, compared to 1757894400 on 15043149. Therefore, it implies a Short% of Shares Outstanding of 16276722 and a Short% of Float of 13.22.
Earnings Estimates
The market rating of Cogent Biosciences Inc (COGT) is currently shaped by the ongoing analysis conducted by 1.0 analysts closely monitoring its performance.The consensus estimate for the next quarter is -$0.54, with high estimates of -$0.41 and low estimates of -$0.62.
Analysts are recommending an EPS of between -$2.51 and -$2.51 for the fiscal current year, implying an average EPS of -$2.51. EPS for the following year is -$1.81, with 12.0 analysts recommending between -$0.89 and -$2.41.
